TABLE 1.
Screening of C. gattii and C. neoformans subpopulations with increased tolerance of tebuconazolea
| Strain | MICsolid (μg/ml) (geometric mean) | MCA (μg/ml) (geometric mean) | MCA/sub-MICsolid (geometric mean) | |||
|---|---|---|---|---|---|---|
| C. gattii | 30°C | 35°C | 30°C | 35°C | 30°C | 35°C |
| R265 (C) | 2.0 | 1.0 | 7.5 | 2.0 | 7.5 | 4.0 |
| ATCC 24065 (R) | 1.0 | 2.0 | 5.0 | 2.0 | 10.0 | 2.0 |
| ATCC 320608 (R) | 2.0 | 2.0 | 10.0 | 2.0 | 10.0 | 2.0 |
| 547/OTTI/94-PI-10 (E) | 2.0 | 2.0 | 10.0 | 2.0 | 10.0 | 2.0 |
| ICB 181 (E) | 1.0 | 1.0 | 2.0 | 2.0 | 4.0 | 4.0 |
| L24/01 (C) | 2.0 | 2.0 | 10.0 | 2.0 | 10.0 | 2.0 |
| L27/01 (C) | 1.0 | 2.0 | 2.0 | 2.0 | 4.0 | 2.0 |
| L28/02 (C) | 2.0 | 1.0 | 10.0 | 1.0 | 10.0 | 2.0 |
| 1913/ER (C) | 1.0 | 0.5 | 1.5 | 0.75 | 3.0 | 3.0 |
| 196L/03 (C) | 2.0 | 4.0 | 4.0 | 16.0 | 4.0 | 8.0 |
| LMM 818 (C) | 1.0 | 2.0 | 3.5 | 3.0 | 7.0 | 3.0 |
| 23/10893 (C) | 1.0 | 0.5 | 0.75 | 0.5 | 1.5 | 2.0 |
| 29/10893 (C) | 1.0 | 0.5 | 1.5 | 1.0 | 3.0 | 4.0 |
| Range | 1.0–2.0 (1.37) | 0.5–4.0 (1.30) | 0.75–10.0 (3.80) | 0.5–16.0 (1.81) | 1.5–10.0 (5.53) | 0.5–8.0 (2.78) |
| C. neoformans | 30°C | 35°C | 30°C | 35°C | 30°C | 35°C |
| H99 (C) | 1.0 | 1.0 | 2.0 | 2.0 | 4.0 | 4.0 |
| ATCC 24067 (R) | 0.5 | 2.0 | 2.0 | 2.0 | 8.0 | 2.0 |
| ATCC 28957 (R) | 1.0 | 2.0 | 10.0 | 2.0 | 20.0 | 2.0 |
| ATCC 62066 (R) | 1.0 | 2.0 | 2.0 | 2.0 | 4.0 | 2.0 |
| Range | 0.5–1.0 (0.84) | 1.0–2.0 (1.68) | 2.0–10.0 (2.99) | 2.0 (2.0) | 4.0–20.0 (7.11) | 2.0–4.0 (2.38) |
a
MICsolid, MIC in solid medium for tebuconazole (TBZ) before the adaptation process; MCA, maximum concentration of tebuconazole achieved in the TBZ adaptation test; C, clinical strain; R, reference strain; E, environmental strain.